Ruth Allen

Herbert Smith Freehills (London)
Lawyer

Ruth is a professional support lawyer in the competition, regulation and trade practice at Herbert Smith Freehills LLP, based in London. She provides technical advice to clients and colleagues on issues of both substantive competition law and procedure, and is also responsible for know-how resources and training programmes. Ruth previously worked as an associate in the team, and has a wide range of both contentious and non-contentious experience across all aspects of EU and UK competition law. She has a particular interest in competition litigation.

Linked authors

Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (London)

Articles

1174 Bulletin

Veronica Roberts, Daniel Vowden, Ruth Allen, Kristien Geeurickx The UK Competition Authority announces its provisional clearance of a proposed acquisition of a stake in a food delivery company in its first application of “failing firm” defence during the COVID-19 pandemic (Amazon / Deliveroo)

896

On 17 April 2020 the CMA announced its provisional clearance of Amazon’s proposed acquisition of a stake in Deliveroo. The transaction was referred for an in-depth Phase 2 investigation in December 2019, in light of concerns about the impact on competition for the supply of online restaurant (...)

Ruth Allen, Kyriakos Fountoukakos, Stephen Wisking The UK Court of Appeal seeks to reinstate record fines totaling £89.4m imposed on pharmaceutical companies for abuse of dominant position through excessive and unfair pricing of an anti-epilepsy drug (Flynn Pharma / Pfizer)

70

On 10 March 2020 the UK Court of Appeal handed down its hotly anticipated judgment in Flynn Pharma Limited & Anr vs Competition and Markets Authority. The UK Competition and Markets Authority (CMA) was seeking to reinstate record fines totalling £89.4m imposed on pharmaceutical companies (...)

Kyriakos Fountoukakos, Dafni Katrana, Ruth Allen The EU Court of Justice clarifies the criteria for the "pay-for-delay" agreements in the pharmaceutical sector (Generics - UK)

147

On 30 January 2020 the European Court of Justice (“ECJ”) clarified for the first time the criteria governing whether so-called “pay-for-delay” agreements entered into between originator and generic pharmaceutical companies fall foul of EU competition law rules. Such agreements are a form of patent (...)

Send a message